Skip to main content
. Author manuscript; available in PMC: 2014 Jul 7.
Published in final edited form as: Nature. 2008 Sep 17;455(7217):1205–1209. doi: 10.1038/nature07284

Figure 3. Genetic ablation of GSK3-β hypersensitizes MLL-transformed cells to pharmacological GSK3 inhibition.

Figure 3

a, Western blot analysis demonstrates the amounts of GSK3 protein isoforms in wild type or Gsk3b−/− myeloid progenitors transformed by the indicated oncogenes. b, Wild type (+/+) or Gsk3b−/− (−/−) myeloid progenitors transformed by various oncogenes were incubated in the presence of the indicated concentrations of SB216763. Cell numbers were enumerated on day 2 and expressed as the fold change compared to day 0 (± s.e.m. of triplicate analyses). c, Western blot analysis demonstrates the relative amounts of β-catenin after treatment with the indicated concentrations (μM) of inhibitor in wild type (WT) or Gsk3b−/− myeloid progenitors transformed by MLL–ENL. d, Gsk3b−/− myeloid progenitors transformed by MLL oncogenes were stably transduced with Flag–GSK3-β (+) or vector (−), and then incubated in the presence or absence of 5 μM SB216763. Cell numbers were enumerated on day 2 and expressed as the fold change compared to day 0 (± s.e.m. of triplicate analyses).